These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 37499216)
1. Two patients with fluoropyrimidine overdose successfully managed without uridine triacetate. Kats CJ; Jochems A; Jeurissen FJ; Ledeboer A; van den Berg RB J Oncol Pharm Pract; 2023 Dec; 29(8):2037-2040. PubMed ID: 37499216 [TBL] [Abstract][Full Text] [Related]
2. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Ma WW; Saif MW; El-Rayes BF; Fakih MG; Cartwright TH; Posey JA; King TR; von Borstel RW; Bamat MK Cancer; 2017 Jan; 123(2):345-356. PubMed ID: 27622829 [TBL] [Abstract][Full Text] [Related]
3. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency. Saif MW; Diasio RB Cancer Chemother Pharmacol; 2016 Jul; 78(1):151-6. PubMed ID: 27278667 [TBL] [Abstract][Full Text] [Related]
4. Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency. Garcia RAG; Saydoff JA; Bamat MK; von Borstel RW Toxicol Appl Pharmacol; 2018 Aug; 353():67-73. PubMed ID: 29908244 [TBL] [Abstract][Full Text] [Related]
5. Case report of capecitabine toxicity and use of uridine triacetate. Oliver WD; Duffy AP; Hausner PF J Oncol Pharm Pract; 2019 Mar; 25(2):470-473. PubMed ID: 28942723 [TBL] [Abstract][Full Text] [Related]
6. The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate. Santos C; Morgan BW; Geller RJ Am J Emerg Med; 2017 May; 35(5):802.e7-802.e8. PubMed ID: 27884585 [TBL] [Abstract][Full Text] [Related]
7. Use of uridine triacetate for the management of fluorouracil overdose. McEvilly M; Popelas C; Tremmel B Am J Health Syst Pharm; 2011 Oct; 68(19):1806-9. PubMed ID: 21930638 [TBL] [Abstract][Full Text] [Related]
8. Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate. Vaudo CE; Gil B; Galuski K; Zarwan C; Nugent FW Pharmacotherapy; 2016 Nov; 36(11):e178-e182. PubMed ID: 27716991 [TBL] [Abstract][Full Text] [Related]
9. Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA? Lampropoulou DI; Laschos K; Amylidi AL; Angelaki A; Soupos N; Boumpoucheropoulos S; Papadopoulou E; Nanou E; Zidianakis V; Nasioulas G; Fildissis G; Aravantinos G J Oncol Pharm Pract; 2020 Apr; 26(3):747-753. PubMed ID: 31382864 [TBL] [Abstract][Full Text] [Related]
10. FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs. Ison G; Beaver JA; McGuinn WD; Palmby TR; Dinin J; Charlab R; Marathe A; Jin R; Liu Q; Chen XH; Ysern X; Stephens O; Bai G; Wang Y; Dorff SE; Cheng J; Tang S; Sridhara R; Pierce W; McKee AE; Ibrahim A; Kim G; Pazdur R Clin Cancer Res; 2016 Sep; 22(18):4545-9. PubMed ID: 27401247 [TBL] [Abstract][Full Text] [Related]
11. Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature. Zurayk M; Keung YK; Yu D; Hu EH J Oncol Pharm Pract; 2019 Jan; 25(1):234-238. PubMed ID: 28950804 [TBL] [Abstract][Full Text] [Related]
12. Vistogard (Uridine Triacetate): The First and Only Drug Approved for the Treatment of 5-Fluorouracil or Capecitabine Overdose: Implications for the Clinical Nurse Specialist. O'Malley PA Clin Nurse Spec; 2016; 30(3):145-7; quiz E11. PubMed ID: 27055035 [No Abstract] [Full Text] [Related]
13. Case report: Uridine triacetate in the management of delayed onset 5-fluorouracil toxicity: A case report and review of literature. Jacob A; Sekkath Veedu J; Selene I; Raj R; Kannan L; Patel R Front Pharmacol; 2022; 13():977734. PubMed ID: 36160401 [TBL] [Abstract][Full Text] [Related]
14. Oral Capecitabine Exposures and Use of Uridine Triacetate: A 20-Year Retrospective Analysis. Seltzer JA; Friedman NA; Hardin J; Galust H; Cantrell FL; Minns A Clin Drug Investig; 2023 May; 43(5):359-363. PubMed ID: 37072662 [TBL] [Abstract][Full Text] [Related]
15. In brief: uridine triacetate (Vistogard) for fluorouracil overdose. Med Lett Drugs Ther; 2016 Jul; 58(1498):90. PubMed ID: 27348145 [No Abstract] [Full Text] [Related]
16. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537 [TBL] [Abstract][Full Text] [Related]
17. 5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration. Brutcher E; Christensen D; Hennessey Smith M; Koutlas JB; Sellers JB; Timmons T; Thompson J Clin J Oncol Nurs; 2018 Dec; 22(6):627-634. PubMed ID: 30451997 [TBL] [Abstract][Full Text] [Related]